OCRA Announces Game-Changing Initiatives This month, OCRA announced a trio of initiatives that carry profound implications for ovarian cancer and related research and patient support: OCRA will expand its mission to include related gynecologic cancers, will create the first comprehensive ovarian and endometrial cancer registry, and will initiate a groundbreaking international data commons. Audra Moran, President and CEO of … Continued
Special Registration for National Conference Ends Thursday, August 31st OCRA’s Ovarian Cancer National Conference returns virtually on November 1st – 3rd with important updates on research, care, and resources from top experts in the field. Topics will include new treatment developments, symptom management, caregiver concerns, and more, with interactive sessions and opportunities to connect. Regular $75 registration begins … Continued
This action alert has now expired. This shortage of chemotherapy drugs, including cisplatin and carboplatin, has reached a serious level, impacting the treatment options available to some ovarian cancer patients. But you can help. In response, Representatives Ami Bera (D-CA), Mike Kelly (R-PA), Derek Kilmer (D-WA), and Brian Fitzpatrick (R-PA) have authored a Dear Colleague … Continued
As many are aware, the United States is currently experiencing a matter of great concern: an ongoing shortage of chemotherapy drugs that are essential in the treatment of ovarian cancer. The availability of these medications is of critical importance to patients and their families, and we understand the anxiety and uncertainty this shortage may cause. … Continued
We hope you’re feeling the love from the teal community this week, and always. We’re just seven weeks into 2023 and there’s so much to share — new grantees, a new website, and a bold, new direction in the fight against ovarian cancer. Research Advocacy Patient Support Ways to Give Did you know there are three simple ways … Continued
When a person is diagnosed with ovarian cancer, their whole world is often turned upside down. As they work to overcome that diagnosis, the last thing they should be worrying about is whether they can afford to pay for their treatment. Unfortunately, many patients are faced with this dilemma, with some drugs that cost well … Continued
The following is a statement from The White House, published on July 13, 2022. Today, President Joe Biden announced his intent to appoint Dr. Mitchel Berger, Dr. Carol Brown, and Dr. Elizabeth Jaffee to the President’s Cancer Panel. The three are distinguished members of the scientific, research, and public health communities appointed by the President … Continued
In a promising development for our community, the House Appropriations Committee recently approved the fiscal year 2023 Labor, Health and Human Services, Education, and Related Agencies bill, which contains significant funding increases for key ovarian cancer programs. We urge the Senate to support these same FY23 program funding levels, which can make a crucial difference … Continued
OCRA has joined 71 other organizations in signing on to a letter calling for the U.S. Senate to incorporate critical reforms into the Prescription Drug User Fee Act (PDUFA) reauthorization which, if implemented, would improve diversity in clinical trials. These reforms, which are included as provisions in the U.S. House version, would make a number of … Continued
Urge your Senators TODAY to co-sponsor a $50 million budget — a $5 million funding increase over current levels — for the federal Ovarian Cancer Research Program! This April, we asked for our community’s help in collecting signatures on a bipartisan Dear Colleague letter in the House of Representatives requesting a major funding increase to the Ovarian … Continued
We need your help today to ensure that a critical ovarian cancer research program is adequately funded. The congressional appropriations process for the 2023 fiscal year is well underway and the ovarian cancer community is requesting $50 million for the Ovarian Cancer Research Program (OCRP) at Department of Defense (DoD), a $5 million increase over current funding levels. … Continued
Update: On 3/11/22, President Biden SIGNED the FY2022 spending bill into law, implementing key ovarian cancer program increases. This represents a major win for the ovarian cancer community, and we applaud all who lent their voices to earn this victory. If you have ever lent your voice on behalf of our shared mission, you — … Continued
Get email updates about research news, action alerts, and ways to join the fight.
